Molecular structure of XL-184 free base, CAS Number: 849217-68-1
XL-184 free base (CAS 849217-68-1)
See product citations (1)
Alternate Names:
Cabozantinib
Application:
XL-184 free base is a potent VEGFR2 and Met inhibitor
CAS Number:
849217-68-1
Purity:
≥98%
Molecular Weight:
501.51
Molecular Formula:
C28H24FN3O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
XL-184 free base (Cabozantinib) is a potent Flk-1 (VEGFR2) inhibitor with IC50 of 0.035 nM. XL-184 also displays potent activity against Met, Ret, Kit, FLT1, FLT3, FLT4, Tie2, and AXL. XL-184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. By inhibiting kinases and other proteins like mTOR, RhoA, and PI3K, XL-184 can inhibit tumor growth and metastasis.
XL-184 free base (CAS 849217-68-1) References
- Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). | Bowles, DW., et al. 2011. Drugs Today (Barc). 47: 857-68. PMID: 22146228
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. | Choueiri, TK., et al. 2015. N Engl J Med. 373: 1814-23. PMID: 26406150
- Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. | Schmidinger, M. and Danesi, R. 2018. Oncologist. 23: 306-315. PMID: 29146618
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. | Choueiri, TK., et al. 2018. Eur J Cancer. 94: 115-125. PMID: 29550566
- Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. | Martínez Chanzá, N., et al. 2019. Lancet Oncol. 20: 581-590. PMID: 30827746
- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. | Italiano, A., et al. 2020. Lancet Oncol. 21: 446-455. PMID: 32078813
- Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Fisher, MJ., et al. 2021. Nat Med. 27: 165-173. PMID: 33442015
- A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. | Pal, SK., et al. 2021. Lancet. 397: 695-703. PMID: 33592176
- Cabozantinib: An evolving therapy for hepatocellular carcinoma. | El-Khoueiry, AB., et al. 2021. Cancer Treat Rev. 98: 102221. PMID: 34029957
- Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. | Hirsch, L., et al. 2021. JAMA Oncol. 7: 1815-1823. PMID: 34673916
- Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. | McGregor, B., et al. 2022. Cancer Treat Rev. 103: 102333. PMID: 35033866
- Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. | Esteban-Fabró, R., et al. 2022. Clin Cancer Res. 28: 2449-2460. PMID: 35302601
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. | Kelley, RK., et al. 2022. Lancet Oncol. 23: 995-1008. PMID: 35798016
- Targeted Therapies in Pheochromocytoma and Paraganglioma. | Wang, K., et al. 2022. J Clin Endocrinol Metab. 107: 2963-2972. PMID: 35973976
- Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. | Brose, MS., et al. 2022. Cancer. 128: 4203-4212. PMID: 36259380
Inhibitor of:
2900062L11Rik, 3110052M02Rik, 7420461P10Rik, ALG11, Angiogenesis, ASPH, BAALC, BSPH1, CYHR1, DDR2, EG-VEGF, EGFL6, EGFL7, ETL, F8A3, FHL-5, Flk-1, Flt-3/Flk-2, FLTR1, Gm2897, H2-Kk, HBV xAg, HCCA2, Hepatocellular Carcinoma Marker, HGFL α, HHCM, KRAP, MACC1, Met, MMD, MOX-1, NET-2, neuropilin, NK10, Olfr1253, Olfr209, Olr1029, Olr1059, Olr1063, Olr110, Olr1125, Olr1126, Olr1217, Olr1234, Olr1245, Olr125, Olr1259, Olr1264, Olr129, Olr1292, Olr1293, Olr1295, Olr1323, Olr1350, Olr1353, Olr1397, Olr1404, Olr1558, Olr1562, Olr157, Olr1622, Olr164, Olr1642, Olr175, Olr232, Olr272, Olr309, Olr322, Olr348, Olr354, Olr363, Olr37, Olr382, Olr390, Olr496, Olr500, Olr517, Olr554, Olr561, Olr592, Olr607, Olr608, Olr668, Olr704, Olr72, Olr724, Olr733, Olr744, Olr768, Olr773, Olr788, Olr836, Olr838, Olr889, Olr92, OVCA1, PATE-N, PDGFR-beta, PIG-F, Ppp2r3d, PSCA, Renal Cell Carcinoma, Ret, RETL2, RNF213, Rse, RUSC2, SEF14, Slap, Sm D1, Srb4, StARD9, TEM7, TEM7R, Tie-1, TRBV3, TSHR, Vasohibin-2, VEGF, VEGF-D, VG5Q, VHR, Vmn2r5, and VSIG10.Activator of:
ARL8, C17orf49_0610010K14Rik, CEACAM6, CUG-BP2, HGFL, LPAAT-γ, PlGF, RAM, and Ron.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
XL-184 free base, 5 mg | sc-364657 | 5 mg | $92.00 | |||
XL-184 free base, 10 mg | sc-364657A | 10 mg | $204.00 |